ILSE Intralase Corp (MM)

IntraLase(R) Corp. (NASDAQ:ILSE) announced today that it will report its 2006 second quarter results on Wednesday, July 26, 2006. A news release will be issued and will also be posted on the company's website at www.intralase.com. Also on July 26, IntraLase will hold an investor conference call at 11:00 a.m. Eastern Time to discuss the company's results. Hosting the call will be Robert J. Palmisano, President and Chief Executive Officer, and Shelley B. Thunen, Executive Vice President and Chief Financial Officer. The conference call will be webcast live and can be accessed on the IntraLase website. The webcast is available to both institutional and individual investors. Individual investors can access the webcast at: www.fulldisclosure.com. Institutional investors can access the webcast via a password-protected event management site at www.streetevents.com. The live call may also be accessed by telephone at 866-383-8008 or for international parties at 617-597-5341 and entering the confirmation code 83204316 between 10:50 a.m. and 11:00 a.m. Eastern Time. The webcast will be archived and available for replay until 5:00 p.m. Pacific Time on August 2, 2006. A telephone rebroadcast of the call may be accessed July 26, 2006 approximately one hour after the conference call concludes for a one-week period by calling 888-286-8010 or for international parties 617-801-6888 and entering confirmation code 88810386. About IntraLase Corp. IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase's computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasties and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company's proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 26 other countries. IntraLase is headquartered and manufactures its products in Irvine, California. For additional information, visit the company's website: www.intralase.com.